Russia may introduce criminal responsibility for 'unfounded drug price' increases

8 August 2016

Russian President Vladimir Putin has instructed the national Federal Anti-Monopoly Service (FAS) and the federal government to continue regular monitoring of drug prices in the domestic market, as well as their compliance with the current market realities, according to recent statements of the press-service of the Russian Presidential Administration, reports The Pharma Letter’s local correspondent.

According to Mr Putin’s instructions, the report about the current situation on prices in the Russian drug market should be provided for his consideration by September 15 of the current year.

According to state plans, on the basis of the report, the Russian government plans to take a decision about its further pricing policy in the domestic pharmaceutical market and may even introduce a criminal responsibility for the unfounded prices’ increase.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK